Clinical perspectives: Treating spinal muscular atrophy.

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disorder.
• Untreated SMA leads to significant weakness and mortality.
• Recent advancements have yielded three approved, high-cost treatments since 2016.

Purpose of the Study:

• To review the evidence supporting current SMA treatments.
• To discuss treatment selection, administration challenges, and monitoring.
• To highlight the limited comparative data and future research needs.

Main Methods:

• Literature review of studies on nusinersen, onasemnogene abeparvovec, and risdiplam.
• Analysis of treatment efficacy, administration routes, and patient monitoring.
• Synthesis of current data on comparative effectiveness and future therapeutic strategies.

Main Results:

• Three effective treatments (nusinersen, onasemnogene abeparvovec, risdiplam) are available for SMA.
• These treatments differ in administration methods and present unique challenges.
• Direct comparative data between these therapies is limited.

Conclusions:

• Current SMA treatments have transformed patient outcomes.
• Treatment selection requires careful consideration of individual patient factors.
• Further research is needed to directly compare therapies and optimize SMA management.